Radiographic Contrast Agent Nephropathy
13
0
0
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
15.4%
2 terminated out of 13 trials
75.0%
-11.5% vs benchmark
46%
6 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
The Effect of the Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During TAVI
Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)
Does Bicarbonate in Addition to Theophylline Reduce CIN?
Relationship Between ALDH2 and CIN
NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial
Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy
Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy
Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP
Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy
Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate
RenalGuard System for Prevention of Contrast Induced Nephropathy
N-Acetyl Cystein and Contrast Nephropathy
Comparing Effects of Patient-specific Versus Non-patient-specific Computerized Reminder System